Submission Deadline: 15 February 2024 (Status: Closed)
Special Issue Editor(s)
Dr. Carlos A. Rubio
Email
|
Website
Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden
Interests:
pathology of esophagus; stomach; duodenum and colon and rectum; cancer induced in experimental animals
Special Issue Information
Dear Colleagues,
This special issue of Discovery Medicine deals with advances on the pathology and molecular attributes of ulcerative colitis (UC) and Crohn’s disease (CD), two diseases usually referred to as inflammatory bowel disease (IBD).
Despite that “simple idiopathic colitis” (UC) and CD of the colorectum were described 164 and 91 years ago, respectively, their etiology remains elusive.
IBD patients are prone to develop colorectal cancer. Therefore, patients are enrolled in endoscopic surveillance programs during which colorectal biopsies are being harvested to detect dysplastic lesions before invasive carcinoma ensues.
Recent research revealed: i) a reproducible morphologic classification of IBD-dysplasia, ii) morphologic changes in IBD, as well as advances in: iii) molecular genetics, iv) gut microbiota-derived metabolites in IBD-associated colorectal cancer, and v) stem cell-based therapy for refractory IBD patients.
Research papers (Original manuscripts or Reviews) dealing with morphologic and molecular clues in IBD, advances in the crosstalk between the colon bacteriome and the host, as well as in stem cells in IBD, are welcomed.
Those items will expand the limits of our current knowledge on IBD-associated colorectal cancer and precursor lesions.
Dr. Carlos A. Rubio
Guest Editor
Keywords
IBD; noninvasive dyplasia; classification; cancer risk; molecular biology
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://www.discovmed.com/Journalx_dm/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.
